Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for metabolic state in schizophrenia patients on antipsychotics
NCT04892199Phase 4Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Mar 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in prediabetes, type 2 diabetes mellitus (T2DM). Started Sep 2021; status: active, not recruiting.
02
Drugs
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04892199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892199.